STAT+: A new biotech licensing Chinese drugs with a unique approach gets high-profile backing
Expedition Therapeutics, a new startup hoping to source the best therapies being developed in China and bring them stateside, has secured high-profile backing.
A new startup hoping to source the best therapies being developed in China and bring them stateside has secured early funding from Venrock and BVF Partners.
Expedition Therapeutics has raised an undisclosed amount of seed financing from Venrock, BVF Partners, and Chinese VC firm Lake Bleu Capital. It plans to raise a Series A round once the team has licensed its first batch of drugs, according to founder and CEO Yi Larson.
In particular, Larson is interested in immune and inflammatory disease treatments, as well as bispecific antibody therapies.
